

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington VA 22202, on April 18, 2002

Tami M Procopio



In the application of:

Examiner: To be Assigned

Group Art Unit: To be Assigned

Filing Date: December 31, 2001

For: **ALTERING THE PROPERTIES OF
CELLS OR OF PARTICLES WITH
MEMBRANES DERIVED FROM
CELLS BY MEANS OF
LIPID-MODIFIED PROTEINACEOUS
MOLECULES**

Assistant Commissioner for Patents
Washington, D.C. 20231

This is in response to the Notice to file corrected application papers, dated February 19, 2002, for which a response is set to expire April 19, 2002. Accordingly, this response is timely filed.

Please enter the following Sequence Listing, amendments and remarks.

In the Sequence Listing:

Please insert the attached paper copy of the Sequence Listing as new page 1 in the above-captioned application. A computer-readable copy (CFR copy) of the Sequence Listing accompanies this response.

Amendments

In the Specification:

Please replace the paragraph beginning at page 20, line 22, with the following rewritten paragraph:

--Expression vector pLP2 was constructed by inserting a small hydrophilic linker (Pack, P. et al. 1993, Bio/technology, 11:1271-1277) into vector pLPscH (de Kruif et al. 1996, FEBS lett. 399:232-236), (figure 1a). The full-encoded sequence of the N-terminus of LT-scFv proteins expressed in vector pLP2 is:

MKATKLVLGAVILGSTLLAGCSSNAKIDQPKPSTPPGSSAMA (SEQ ID NO:1).--

REMARKS

The Specification has been amended to include sequence identifications numbers which were omitted at the time of filing.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "**Version with markings to show changes made.**".

The undersigned hereby states that the computer readable form copy (CRF copy) of the Sequence Listing and the paper copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. **313632000801**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: April 18, 2002

By: Kate H. Murashige
Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125

VERSION WITH MARKINGS TO SHOW CHANGES MADE**In the Specification:**

The paragraph beginning at page 20, line 22, has been amended as follows:

Expression vector pLP2 was constructed by inserting a small hydrophilic linker (Pack, P. et al. 1993, Bio/technology, 11:1271-1277) into vector pLPscH (de Kruif et al. 1996, FEBS lett. 399:232-236), (figure 1a). The full-encoded sequence of the N-terminus of LT-scFv proteins expressed in vector pLP2 is:

MKATKLVLGAVILGSTLLAGCSSNAKIDQPKPSTPPGSSAMA (SEQ ID NO:1).